NASDAQ: CRBPCorbus Pharmaceuticals Holdings Inc Stock
$7.26+0.34 (+4.91%)
Updated Sep 16, 2026
CRBP Price
$7.26
Fair Value Price
$2.02
Market Cap
$140.42M
52 Week Low
$6.33
52 Week High
$20.56
P/E
-1.19x
P/B
1.37x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$101.90M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.24
Operating Cash Flow
-$87M
Beta
1.33
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CRBP Overview
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CRBP's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -12.86% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CRBP
Ranked#459 of 461
Ranked#459 of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.39 | A | |
| $42.21 | A | |
| $111.81 | A |
Be the first to know about important CRBP news, forecast changes, insider trades & much more!
CRBP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CRBP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CRBP ($7.26) is overvalued by 259.96% relative to our estimate of its Fair Value price of $2.02 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CRBP ($7.26) is not significantly undervalued (259.96%) relative to our estimate of its Fair Value price of $2.02 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CRBP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CRBP due diligence checks available for Premium users.
Valuation
CRBP fair value
Fair Value of CRBP stock based on Discounted Cash Flow (DCF)
Price
$7.26
Fair Value
$2.02
Overvalued by
259.96%
CRBP ($7.26) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CRBP ($7.26) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CRBP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CRBP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.19x
Industry
9.99x
Market
44.18x
CRBP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.37x
Industry
5.23x
CRBP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CRBP's financial health
Profit margin
Revenue
$0.0
Net Income
-$35.0M
Profit Margin
0%
CRBP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$127.0M
Liabilities
$24.7M
Debt to equity
0.24
CRBP's short-term assets ($122.75M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRBP's short-term assets ($122.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRBP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CRBP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$29.6M
Investing
$18.3M
Financing
$0.0
CRBP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CRBP vs Biotech Stocks
Corbus Pharmaceuticals Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.